新近提出的预后分级指数——脑转移速度(BMV)在多次立体定向放射外科治疗脑转移患者中的有效性验证
本研究回顾性分析833例接受第二次立体定向放射外科(SRS)的脑转移患者,验证脑转移速度(BMV)评分系统的预后价值。BMV按首次SRS后新发脑转移累积数除以时间(年)计算,分为≤3、4-13、≥14三组。结果显示BMV可预测第二、三、四次SRS后的生存,且小细胞肺癌患者平均BMV评分显著高于非小细胞肺癌患者。
要点
- BMV评分≤3、4-13、≥14三组第二次SRS后中位生存期分别为12.9、7.5、5.1个月(P=.0001)。
- 第三次SRS后三组中位生存期分别为13.2、8.0、5.7个月(P=.0001)。
- 小细胞肺癌患者平均BMV评分24.8显著高于非小细胞肺癌患者17.7(P=.032)。
核心结论
- 本研究结果支持BMV不仅可预测第二次SRS后的生存,也可预测第三次和第四次SRS后的生存。
研究设计与样本
- 本研究为回顾性队列研究,经东京女子医科大学机构审查委员会批准(编号1981),使用前瞻性积累的数据库。
- 纳入833例接受第二次SRS(伽玛刀)治疗新发现病灶的脑转移患者,排除接受全脑放疗者。
- 手术实施时间为1998年7月至2017年6月共19年期间;833例中250例接受第三次SRS,88例接受第四次SRS。
主要发现
- 第二次SRS后中位生存期:BMV≤3组为12.9个月(95%CI 10.2-17.1),4-13组为7.5个月(95%CI 6.5-9.0),≥14组为5.1个月(95%CI 4.0-5.6),P=.0001。
- 第三次SRS后中位生存期:三组分别为13.2个月(95%CI 9.1-21.6)、8.0个月(95%CI 6.2-11.2)、5.7个月(95%CI 4.8-7.8),P=.0001。
- 第四次SRS后中位生存期:三组分别为13.2个月(95%CI 9.1-21.6)、8.0个月(95%CI 6.2-11.2)、5.7个月(95%CI 4.8-7.8),P<.0001。
- 小细胞肺癌患者平均BMV评分为24.8,显著高于非小细胞肺癌患者的17.7(P=.032)。
关键数值与推荐
- BMV评分定义为首次SRS后新发脑转移的累积数量除以自首次SRS以来的时间(年)。
- 患者按BMV评分分为3类:≤3、4-13、≥14。
- 第二次SRS后中位生存期BMV≤3组12.9个月(95%CI 10.2-17.1)vs 4-13组7.5个月(95%CI 6.5-9.0)vs ≥14组5.1个月(95%CI 4.0-5.6),P=.0001。
- 第三次SRS后中位生存期BMV≤3组13.2个月(95%CI 9.1-21.6)vs 4-13组8.0个月(95%CI 6.2-11.2)vs ≥14组5.7个月(95%CI 4.8-7.8),P=.0001。
- 第四次SRS后中位生存期BMV≤3组13.2个月(95%CI 9.1-21.6)vs 4-13组8.0个月(95%CI 6.2-11.2)vs ≥14组5.7个月(95%CI 4.8-7.8),P<.0001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study of our patients with brain metastasis who underwent multiple stereotactic radiosurgery (SRS) procedures aimed to validate whether the recently proposed prognostic grading system, brain metastasis velocity (BMV), is generally applicable. The BMV scores the cumulative number of new brain metastases that developed after the first SRS divided by time (years) since the initial SRS. Patients were categorized into 3 classes by their BMV scores (ie, ≤3, 4-13, and ≥14). METHODS AND MATERIALS: This retrospective cohort study was approved by the Tokyo Women's Medical University Institutional Review Board (number 1981). We used our prospectively accumulated database, which included 833 patients who underwent a second SRS procedure for newly detected lesions, using a gamma knife, for brain metastases. Patients who had whole-brain radiation therapy were excluded. The procedures took place during the 19-year period between July 1998 and June 2017. Furthermore, among the 833 patients, 250 underwent a third SRS procedure, and 88 had a fourth SRS procedure. RESULTS: The median survival times (MSTs) after the second SRS were 12.9 months (95% confidence interval [CI], 10.2-17.1) for the BMV group with a score of ≤3; 7.5 months (CI, 6.5-9.0) for the group scoring 4 to 13, and 5.1 months (CI, 4.0-5.6) for the group scoring ≥14 (P = .0001). The corresponding MSTs after the third SRS were 13.2 months (95% CI, 9.1-21.6), 8.0 months (CI, 6.2-11.2), and 5.7 months (CI, 4.8-7.8; P = .0001). Respective MSTs after the fourth SRS were 13.2 months (95% CI, 9.1-21.6), 8.0 months (CI, 6.2-11.2), and 5.7 months (CI, 4.8-7.8; P < .0001). The mean BMV score of patients with small cell lung cancer, 24.8, was significantly higher than that of patients with non-small cell lung cancer, 17.7 (P = .032). CONCLUSIONS: Our present results support the validity of BMV for predicting survival not only after the second SRS but also after the third and fourth SRS.
引用
- Yamamoto M, Aiyama H, Koiso T, et al. Validity of a Recently Proposed Prognostic Grading Index, Brain Metastasis Velocity, for Patients With Brain Metastasis Undergoing Multiple Radiosurgical Procedures. Int J Radiat Oncol Biol Phys. 2018. PMID: 30395905. doi:10.1016/j.ijrobp.2018.10.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。